_ Stockhead's SarahHughan chats with AdAlta CEO Tim Oldham about the company’s recent appointments of consultant chief medical officers for its AdCella and AdSolis subsidiaries, as well as the progress of its AD-214 program. Watch the interview here: stockhead.com.au/stockhead-tv/l…

AdAlta recognises the sustained efforts of its Analytical Scientist Arfatur Rahman, a key member of the analytical team that characterises i-bodies and other proteins to assess their purity and binding strength to target receptors.

AdAlta (ASX:1AD) has announced Ms Michelle Burke and Mr Iain Ross have been appointed to the AdAlta Board as Non-Executive Directors to support the continued execution of the Company’s strategy | ASX announcement: investorhub.adalta.com.au/announcements/…

AdAlta (ASX:1AD) CEO & MD Tim Oldham joins IPF survivor Bill van Nierop in the Stockhead TV studio to discuss the devastating impact of IPF & how AdAlta's innovative i-body drug candidate, AD-214, is poised to revolutionise treatment | Watch it here stockhead.com.au/stockhead-tv/w…

AdAlta focused on AD-214 ROI & "east to west" cell therapy growth. CEO & MD Tim Oldham recently spoke with Tony Locantro of Alto Capital about his confidence in the near term potential for deals for both AD-214 and the cell therapy strategy | Listen here:  youtu.be/fuMthT8Np98

AdAlta has been featured on Stockhead's Road to 2025 video series, which highlights companies' key 2024 achievements & is set to unlock value from its AD-214 asset and expand its pipeline through its "East to West" cell therapy strategy in 2025 |  stockhead.com.au/stockhead-tv/r…

AdAlta is featured on Stockhead 's Tony Locantro's Takeaway: New year nuggets for biotech-hungry investors. 1AD was in his top 5 biotechs to watch in 2025, citing the promising potential for commercialisation of AD-214 product addressing IPF | stockhead.com.au/stockhead-tv/t…

AdAlta (ASX:1AD) CEO & MD Tim Oldham has just completed a successful US partner and investor roadshow. He presented at Biotech Showcase as part of JPMorgan Healthcare Week in San Francisco and visited San Diego, New York and Boston.

AdAlta has released its quarterly, with highlights including: - Expanded advisor network engaged to support “East to West” cellular therapy strategy - First non-binding term sheet executed for “East to West” cellular therapy strategy ASX announcement: investorhub.adalta.com.au/announcements/…

AdAlta advanced both its East to West cellular immunotherapy strategy and AD-214, its first-in-class anti-fibrotic drug candidate, over Q2 FY25. Board renewal & new hires in AdAlta’s advisor team during Q2 FY25 - Stockhead reports | Read more: stockhead.com.au/health/adalta-…

AdAlta is presenting at the 3rd ANZ Biologics Festival being held in Melbourne from 4-5 Feb, 2025. CEO & MD Tim Oldham, is presenting a paper entitled “Market Trends & Investment Landscape for Cell and Gene Therapy in ANZ” | ASX announcement: investorhub.adalta.com.au/announcements/…

AdAlta accelerates its “East to West” cellular immunotherapy growth strategy with the execution of two further non-binding term sheets to in-license clinical stage CAR-T products, bringing total products in exclusive due diligence to three. investorhub.adalta.com.au/announcements/…

AdAlta will host an investor webinar on Tuesday 11 February at 12pm. In the webinar CEO & MD Dr Tim Oldham will discuss the results of AdAlta’s strategic review and portfolio prioritization. ASX announcement: investorhub.adalta.com.au/announcements/… Register here: us02web.zoom.us/webinar/regist…

"AdAlta has ranked its East to West cellular immunotherapy strategy as its core growth priority, saying that it is the key driver of future pipeline growth and value creation" - Stockhead | Read more: stockhead.com.au/health/adalta-…

Stockhead’s Fraser Palamara chats with AdAlta CEO & MD Tim Oldham about the “East to West” strategy that leverages the incredible innovation coming out of Asia generally and China especially, in the rapidly growing cellular immunotherapies market segment stockhead.com.au/stockhead-tv/l…

AdAlta (ASX:1AD) hosted an investor webinar on Tuesday 11 February 2025. The webinar presented by AdAlta’s CEO & MD, Tim Oldham. In the webinar Dr Oldham discussed the results of AdAlta’s strategic review and portfolio prioritization | Watch the it here: youtu.be/Hpv0j8MIESs

AdAlta is thrilled to be presenting at the upcoming 4th BioCentury-BayHelix East-West Biopharma Summit in Singapore which will take place 4-5 March 2025. For more information visit: conferences.biocentury.com/east-west-summ…

AdAlta (ASX:1AD) receives $0.42m advance on its FY25 R&D Tax Incentive rebate. These new funds will help support due diligence and definitive agreements for ”East to West” cellular immunotherapy assets. ASX announcement: investorhub.adalta.com.au/announcements/…